State attorneys general want to lower Gilead's high remdesivir prices with federal patent law
The antiviral drug remdesivir's effectiveness at combating the coronavirus has been one of the biggest breakthroughs since the pandemic began. The catch is that the Gilead treatment is expensive and in short supply. So, a bipartisan group of state attorneys general are looking to the federal government to step in and change that.
In a letter to the heads of the Department of Health and Human Services, the National Institutes of Health, and the Food and Drug Administration, 31 attorneys general asked the agencies to exercise march-in rights granted to them by the 1980 Bayh-Dole Act to increase the supply of the drug and lower the price so it becomes more accessible to Americans.
The bill allows federal agencies to retain patent rights for drugs developed from federal funds, which Gilead received to boost remdesivir during the pandemic, if the manufacturer fails to achieve a reasonable price or "alleviate health or safety needs" of consumers. In this case, the letter argues, "it is clear that Gilead" has not done either of those things. Read the full letter here and more on the issue at USA Today.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
US charges Indian tycoon with bribery, fraud
Speed Read Indian billionaire Gautam Adani has been indicted by US prosecutors for his role in a $265 million scheme to secure solar energy deals
By Peter Weber, The Week US Published
-
Boeing machinists approve contract, end strike
Speed Read The company's largest union approved the new contract offer, ending a seven-week strike
By Peter Weber, The Week US Published
-
US economy still strong in final preelection report
Speed Read It grew at a solid 2.8% annual rate from July through September
By Peter Weber, The Week US Published
-
Boeing machinists reject deal, continue strike
Speed Read The rejection came the same day Boeing reported a $6.2 billion quarterly loss
By Peter Weber, The Week US Published
-
Ports reopen after dockworkers halt strike
Speed Read The 36 ports that closed this week, from Maine to Texas, will start reopening today
By Peter Weber, The Week US Published
-
Empty-nest boomers aren't selling their big homes
Speed Read Most Americans 60 and older do not intend to move, according to a recent survey
By Peter Weber, The Week US Published
-
Brazil accuses Musk of 'disinformation campaign'
Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
By Rafi Schwartz, The Week US Published
-
Disney board fends off Peltz infiltration bid
Speed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
By Rafi Schwartz, The Week US Published